Association of sul genes and class 1 integron with trimethoprimsulfamethoxazole Resistance in Stenotrophomonas maltophilia clinical isolates in Zagazig University, Egypt by Morsi, SS et al.
158 
 
ORIGINAL ARTICLE  
AFRICAN JOURNAL OF CLINICAL AND EXPERIMENTAL MICROBIOLOGY     JULY  2016   ISBN 1595-689X      VOL17 No. 3                 
AJCEM/1623    http://www.ajol.info/journals/ajcem                                         
COPYRIGHT 2016 http://dx.doi.org/10.4314/ajcem.v17i3.1                                                                                                                                                                                                                                                                                                                            
AFR. J. CLN. EXPER. MICROBIOL. 17 (3): 158- 165 
 
ASSOCIATION OF SUL GENES AND CLASS 1 INTEGRON WITH TRIMETHOPRIM-
SULFAMETHOXAZOLE RESISTANCE IN STENOTROPHOMONAS MALTOPHILIA CLINICAL 
ISOLATES IN ZAGAZIG UNIVERSITY, EGYPT 
 
Morsi S.S.*, Sharaf H.E.*, Gerges M.A.* 
*Medical Microbiology & Immunology Department, Faculty of Medicine, Zagazig University, Egypt. 
 
Correspondence: Samar Saeed Morsi; samarsaeed_76@yahoo.com 
ABSTRACT 
Background: Stenotrophomonas maltophilia (S.maltophilia) is an intrinsically drug resistant opportunistic pathogen associated 
with serious infections in humans. Acquired resistance to trimethoprim-sulfamethoxazole (SXT,co-trimoxazole), the main stay 
of therapy against S. maltophilia ,has made its treatment more problematic. Objectives: This work aimed to determine the 
occurrence of SXT resistance among S. maltophilia isolated from Zagazig University Hospitals in Egypt and to assess the 
association of sul genes and integron1 with SXT-resistant isolates.                                                                                            
Material and Methods: Thirty-two S.maltophilia isolates were identified in this study during the period from 2013 to 2015. 
Screening of SXT-resistant isolates was done by Kirby-Bauer method. Minimum inhibitory concentration(MIC) values for SXT 
were determined by agar dilution. S. maltophilia isolates were tested for the presence of sul1, sul2, sul3, and int 1 genes by 
multiplex polymerase chain reaction.                                                                                    
Results: Amongst the 32 S. maltophilia isolates, 12(37.5%) were resistant to SXT. All SXT-resistant isolates were found to harbor 
sul1 gene and integron1. One of these isolates had sul2 gene (1/12,8.3%). Meanwhile, sul3 gene was not detected in any of the 
SXT-resistant isolates. Only 2 of the 20 SXT-susceptible isolates was found to yield positive PCR results for sul1 gene, one of 
them gave positive result for class 1 Integron. The association of sul genes and Integrin1 with resistance to SXT had a 
statistically significant difference( P<0.0001). Conclusion: Our study indicated a high frequency of SXT resistance among 
clinical S.maltophilia isolates from Zagazig University Hospitals, in which sul genes and class 1 integron were found to have a 
major role. 
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RESUME 
Contexte: Stenotrophomonas maltophilia est un pathogène opportuniste résistant à la drogue intrinsèquement associée à des infections 
graves chez l’homme. Résistance acquise à triméthoprime – sulfaméthoxazole (SXT, co - trimoxazole), le pilier de la thérapie contre S. 
maltophilia, a fait son traitement plus problématique.  
Objectifs : Ce travail visait à déterminer l’apparition de la résistance de SXT chez S. maltophilia isoles des hôpitaux universitaires Zagazig et 
d’évaluer l’association de gènes et intégron 1 avec des isolats résistants à SXT. 
Matériel et Méthodes: Trente – deux isolats de S. maltophilia ont été identifiés dans cette étude pendant la période de 2013 à 2015. Le 
dépistage des isolats SXT a été fait par la méthode Kirby – Bauer. Les concentrations minimales inhibitrices (MIC) pour SXT ont été 
déterminées par dilution gélose. Les isolats S.maltophilia ont été testés pour la présence des gènes de sul 1, sul 2, sul3, par réaction en chaine 
polymérase multiplex. 
Résultats  : Parmi les 32 isolats S.maltophilia, 12 (37,5%) étaient résistants à SXT. Tous les isolats résistants à SXT ont été trouvés d’abriter le 
gène sul1 et intégron 1. L’un de ces isolats a eu le gène sul2 (1/12,8, 3%). Cependant, le gène sul3 n’a pas été détecté dans aucun des isolats 
résistants à SXT. Deux seulement des vingt des isolats sensibles ont été trouvés pour obtenir des résultats positifs de PCR pour le gène 
sul1, l’un d’entre eux a donné des résultats positifs pour la classe d’intégron 1. L’association des gènes de sul et intégron 1 avec une résistance 
à SXT avait une différence statistiquement significative (P<0,0001).  
Conclusion: Notre étude à indiqué une fréquence élevée de résistance à SXT chez S. maltophilia clinique des hôpitaux universitaires 
Zagazig  dans lesquels les gènes sul et intégron 1 ont été trouvés d’avoir un rôle majeur.  Mots clés:  Stenotrophomonas maltophilia ; 
Sulphaméthoxazole–triméthoprime – résistant ; Multiplex PCR ; sul gènes ; intégron 1. 
159 
 
INTRODUCTION                                                                                                                                                               
Stenotrophomonas maltophilia (S.maltophilia) is a glucose 
non fermentative, aerobic, motile Gram negative 
bacillus. It was first isolated in 1943 and named 
Bacterium booker. In 1961, it was re classified as a 
member of the genus Pseudomonas, then Xanthomonas 
in 1983 and later Stenotrophomonas in 1993 (1). It is 
commonly found in various environments such as 
water, soil, plants as well as in hospital settings (2).                                                                                   
 
These bacteria typically colonize areas of the body 
without causing infection. However, in severely ill, 
hospitalized patients, S. maltophilia can cause a wide 
range of serious infections, including nosocomial 
pneumonia, bacteremia, pulmonary infections, 
urinary tract infections, wound infections, skin and 
soft tissue infections, meningitis, and endocarditis, 
particularly with those having impaired immune 
system (1,2). This is facilitated by the organism’s 
ability to survive on almost any humid surface, its 
tendency to form biofilm, and its employment of 
several mechanisms that confer resistance to a 
number of antimicrobial agents (3).  
 
Factors that increase the risk for S. maltophilia 
infection include admission to an intensive care unit, 
prolonged hospitalization, HIV infection, cancer, 
cysticfibrosis, neutropenia, recent surgery, trauma, 
mechanical ventilation, and previous therapy with 
broad-spectrum antibiotics( 4). S. maltophilia has high-
level intrinsic resistance to many antibiotics owing to 
its multidrug-efflux pumps and low outer membrane 
permeability, which makes its infections difficult to 
manage (5). In addition to being intrinsically drug-
resistant pathogen, it can acquire antibiotic resistance 
by horizontal transfer of resistance genes located on 
plasmids, transposons and integrons (5). This has 
made the World Health Organization to classify S. 
maltophilia as one of the leading multidrug resistant 
organisms (MDROs) in hospital settings (6).  
 
Trimethoprim/sulfamethoxazole (SXT, co-
trimoxazole) is considered the first-line agent 
recommended for the treatment of S. maltophilia (7). 
However, SXT resistancein S. maltophilia has been 
widely increasing over recent years (8). This 
constitutes a great clinical problem, ast he range of  
 
 
effective antibiotic agents is even more limited in 
infections caused by co-trimoxazole-resistant S. 
maltophilia (9). Resistance to co-trimoxazole can result 
from mutations in the chromosomal dihydropteroate 




acquisition of an alternative DHPS gene (sul), whose 
product has a lower affinity for sulfonamides (10). 
                                                                                                                             
The sul1 gene is mostly found linked to other 
resistance genes in class 1 integrons, while sul2 is 
usually located on small plasmids.  Sul3, shares an 
amino acid identity of ∼40% with previously known 
resistant enzymes and it is a plasmid borne resistance 
gene. The genetic localization of sul genes on efficient 
mobile genetic structures probably contributes to the 
widespread of sulfonamides resistance (11). As no 
much information is currently available regarding the 
frequency of SXT resistance among S. maltophilia 
isolates in our hospital, this study aimed to determine 
the occurrence of SXT resistance among S. maltophilia 
isolated from Zagazig University Hospitals, Egypt 
and to assess the association of sul genes and integron 
1 with SXT-resistant isolates. 
 
MATERIAL AND METHODS 
Study Design and Patient Selection                                         
Across-sectional study was carried out from June 2013 
to August 2015 during which samples were collected 
according to the site of infection from patients 
admitted to Zagazig University Hospitals. The study 
was conducted in Medical Microbiology and 
Immunology Department, Faculty of Medicine, 
Zagazig University, Egypt. This study was approved 
by the local institutional review board (Zagazig 
University IRB). Urine, sputum, endotracheal 
aspirates (ETA), blood and pus were collected from 
patients located in different medical wards, surgical 
wards and ICUs according to the standard 
microbiological methods. Informed consent was 
obtained from the patients. 
 
Cultivation and Presumptive Identification of 
Stenotrophomonas Isolates                                                                            
Samples were grown on blood and MacConkey agar 
except urine samples, which were grown on CLED 
(Oxoid, UK). Blood samples were collected in blood 
culture bottles containing brain-heart infusion broth 
and then subcultured onto agar plates (Blood and 
MacConkey agar). Non-lactose fermenting colonies 
were identified initially by Gram stain, catalase test, 
oxidase test, then confirmed to be S. maltophilia by 
API20NE (Bio-Mérieux, Marcy L’Etoile, France). 
 
Phenotypic Antibiotic Susceptibility Test 
The Kirby-Bauer disc diffusion method was 
employed to determine the antibiotic susceptibility 
pattern of the isolates using antibiotic discs (Oxoid, 
UK) on Mueller Hinton agar. All isolates were tested 
against gentamicin (10µg), amikacin (30µg), 
levofloxacin (5µg), ciprofloxacin (5µg), imipenem 
(10µg), trimethoprim/sulphamethoxazole (SXT) 
(1.25/23.75µg), pipracillin/tazobactam (100/10µg), 
ceftazidime (30µg) and ticarcillin/clavulanate 
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(75/10µg), tigecycline (30µg) and colistin (10µg). The 
antimicrobial susceptibilities were categorized in 
accordance with the 2012 Clinical Laboratory 
Standard Institute (CLSI) for S. maltophilia. For agents 
without published CLSI criteria for S.maltophilia, the 
relevant criteria for non-Enterobacteriaceae were used 
(12).  
 
Determination of SXT Minimum Inhibitory 
Concentration 
Only isolates that showed resistance to co-
trimoxazole (irrespective of resistance to other 
antibiotics) were selected for minimum inhibitory 
concentration (MIC) determination. MIC values for 
co-trimoxazole were determined by E test according 
the E-test reading guide: where the edge of the 
inhibition ellipse intersects the side of the strip (Bio-
Mérieux, Marcy L’Etoile, France). 
 
Assessment of SXT Resistance Genes 
DNA extraction                                                                                                                                                                                  
A single colony was inoculated into Mueller–Hinton 
broth and incubated for 20 hours at 37C°. After 
centrifugation at 10000×g for 10 minutes (min), each 
pellet was washed three times in 750µl TE buffer 
(10mMTris-HCl, 1mM EDTA, pH 8.0) and then 
resuspended in 500µl TE buffer. The solution was 
boiled for 20 min and centrifuged at 10000×g for 
10min, and the supernatant was then used as a crude 
DNA extract in PCR. Extracted DNA was stored at-
20°C until further processing. 
 
sul1, sul2 and integron 1 detection                                                                                                                                                                       
Multiplex PCR amplification of sul1, sul2 and integron 
1 was conducted as described by Kerrnetal.(13) 
Amplification of sul1 was performed using the 
forward primer sul1f (5′-CGG CGT  GGG CTA CCT 
GAA CG-3′) and reverse primer sul1r (5′-
GCCGATCGCGTGAAGTTCCG-3′) (433bp).sul2 was 
identified using the forward primer sul2-F (5′-GCG 
CTC AAG GCA GAT GGC ATT-3′) and the reverse 
primer sul2-B (5′-GCG TTT GAT ACC GGC ACC 
CGT-3′)(293bp). Integron 1 was amplified by using 
Int-F (5′-GCC ACT GCG CCG TTA CCA CC-3′) and 
Int-B (5′-GGC CGA GCA GAT CCT GCA CG--3′) 
(898bp). Additionally, the 16SrRNA gene (auniversal 
bacterial gene) was amplified in each reaction to serve 
as an internal positive control using the forward 
primer 16S-F (5′-GCG GAC GGG TGA GTA ATG T-
3′) and reverse primer 16S-B (5′-TCA TCC TCT CAG 
ACC AGC TA-3′) (200bp).                                                                          
The PCR mixture contained 5µl of template DNA, 5µl 
of 10×PCR buffer, 10µl of dNTP mix, 4µl of MgCl 2;0 
.25µl of AmpliTaq DNA polymerase, 2.5µl of each 
primer 16S-F, 16S-B (40µM), sul1-F, sul1-B, sul2-F, 
sul2-B, Int-FandInt-B (2µM) and 5.75µl distilled water. 
Amplification was carried out by heating for 5 min at 
94°C, followed by 30 cycles of 94°C for 15s, 69°C for 
30s and 72°C for 60s, followed by one cycle at 72°C for 




Different reaction conditions were used to amplify 
sul3 (14). PCR was performed using a 25µl reaction of 
2µl of boiled lysate, 1×PCR buffer, 3mM MgCl 2,0. 
4mM dNTPs, 1.5U of Taq polymerase, 0.4µM sul3F 
primer (5′-GAG CAA GAT TTT TGG AAT CG-3′) and 
0.4µM sul3R primer (5′-CAT CTG CAG CTA ACC 
TAG GGC TTT GGA-3′) (569bp). Mixtures were 
centrifuged for 30s at 3000 rpm. Cycling conditions 
were 98°C for 1min followed by 35 cycles of 98°C for 
30s, 51°C for 30s and 72°C for 1min. A final extension 
was performed at 72°C for 5 min. 
 
Amplicon detection by agarose gel electrophoresis                                                                                                                            
Ten µl of each amplified DNA & 1500 molecular 
weight marker (Invitrogen, USA) were separated on 
2% agarose gel containing 0.3mg/ml of ethidium
bromide. The bands were visualized using UV 
transilluminator (312nm), photographed & analyzed. 
 
Statistical analysis                                                                                                                              
Data was analyzed using EPI-INFO 6 for data 
processing and statistics. Numerical data were 
expressed as mean and standard deviation. 
Qualitative data were expressed as frequency and 
percentage. Chi square test was used to examine the 
relation between qualitative variables. P value <0.05 
was considered significant. 
RESULTS                                                                                                                                      
A total of 32 non-duplicate clinical isolates of 
S.maltophilia were obtained from 300 patients (32/300, 
10.6%) admitted to different wards and ICUs at 
Zagazig University Hospitals, between 2013 and 2015. 
Isolates were obtained from 18 male (56.25%) and 14 
female (43.75%) with a male/female ratio of 1.3:1. The 
mean age of patients was 64.8±9.65 years (range 48 
years to 87 years). The most frequent site of isolation 
was the respiratory tract (68.7%); including ETA 
(46.87%) & sputum (21.87%) followed by blood 
(18.75%), wound (9.4%) then urine (3.12%) (Table1). 
                                                                                  
The antimicrobial activities of 11 selected antibiotics 
against 32 S. maltophilia isolates are presented in 
Table2. All isolates were sensitive to tigecycline and 
resistant to imipenem. Twelve isolates (37.5%) were 
resistant to SXT. 
 
The sul genes and integron1 were tested in all the 32 
S. maltophilia isolates. All of the 12 SXT-resistant 
isolates harbored sul1 gene and were positive for 
integron 1. One isolate among the resistant isolates 
(1/12) also carried sul2 gene. sul3 gene, on the other 
hand, had not been detected in any of the resistant 
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isolates. Only 2 of the 20 SXT-susceptible isolates was 
found to yield positive PCR results for sul1 gene, one 
of them gave positive result for Integron 1. The 
association of sul genes and Integron 1 with resistance 
to SXT had a statistically significant difference 























TABLE (1): DISTRIBUTION OF S.MALTOPHILIA 
















                                                                                                                                                                                                                                   
TABLE(2): ANTIMICROBIAL ACTIVITIES AGAINST S.MALTOPHILIA ISOLATES 
Antibiotic Sensitive Resistant 
No. % No. % 
TG 32 100 0 0 
CT 27 84.4 5 15.6 
LEV 26 81.25 6 18.75 
SXT 20 62.5 12 37.5 
TIC-CL 20 62.5 12 37.5 
CAZ 20 62.5 12 37.5 
TZP 17 53 15 47 
CIP 15 47 17 53 
AK 13 40.6 19 59.4 
GM 13 40.6 19 59.4 
IPM 0 0 32 100 
 
TG: tigecycline, CT: colistin, LEV: Levofloxacin, SXT: trimethoprim/sulphamethoxazole, TIC-CL: ticarcillin clavulinic acid, 













FIGURE (1): GEL ELECTROPHORESIS RESULTS
LANE 1: MOLECULAR WEIGHT MARKER
strains (Lanes 3, 5, 6 & 7: sul
 
DISCUSSION                                                                                                     
S. maltophilia is an emerging multidrug
opportunistic pathogen. Its intrinsic
resistance to most antibiotics and 
colonize the surfaces of medical devices
a potentially dangerous pathogen 
settings(15). In our study, 32 consecutive
duplicate S. maltophilia isolates were obtained
300 patients between June 2013-August
percentage of 10.6%. Our findings are 
with Samonis et al (16) who identified S.
10% of the studied samples and with
study that revealed S.maltophilia in 9.7%
clinical samples (17). However, ot
reported a lower percentage; Nseiretal.(18)
S. maltophilia isolates in 2% of the clinical
during a three-year study period. This difference
be attributed to different patient population
different underlying risk factors and diseases.
 
In the present study, the frequency of
isolation from respiratory specimen 
aspirate and sputum), blood, wound and
68.7, 18.75, 9.4 and 3.12% respectively. 
agreement with Thabit et al. (17) who reported
Egyptian study, that S. maltophilia was
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20 2(10) 0(0) 0(0) 
12 12(100) 1(8.3) 0(0) 
 
 OF MULTIPLEX PCR ON CLINICAL ISOLATES OF
 100 BP, LANE 2: NEGATIVE CONTROL,  LANE 3-8: amplicons
1, int 1 positive, Lane 4: sul1, sul2, int 1 positive, Lane 8: negative).
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et al .(19) reported that 59% of S.
were from respiratory specimen 
(16.22%), blood (14.87%) and urine
Samonis et al.(16) reported that
infection associated with S. maltophilia
tractinfection (54.4%) followed 
infections (16.2%), skin and soft
(10%) and lastly urinary tract infection
                                                                                 
The variation in the percentages 
may be attributed to the patien
studies whether from the intensive
or from other hospital wards. Most
included in our study were ICU patients,
higher occurrence of infections. Overall,
results in addition to ours agreed
maltophilia may cause many 
infections, the respiratory tract represents
common site affected. 
                                                                                  
The management of S. maltoph
represents a great challenge to
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clinical trials to determine optimal therapy, and its 
intrinsic resistance to a plethora of antimicrobial 
agents, which severely limits the effectiveness of 
commonly used empiric antimicrobial therapies (15).                                                                                                                 
                                                                                                                                                                                                  
In our study, S. maltophilia isolates were tested against 
11 antibiotic to determine their antibiotic sensitivity 
using the disc diffusion method. The most effective 
antibiotics in vitro were tigecycline, colistin, 
levofloxacin, SXT, then ticaricillin-clavulunic and 
ceftazidime, which showed the highest sensitivity 
(62.5%) among the β-lactams used in this study.  
Similar results were obtained by Samonis et al. (16) 
who reported that colistin and tigecycline could be 
considered as new therapeutic options against S. 
maltophilia infections. This is also in line with Zhanel 
et al. (20) who stated that tigecycline displayed good 
in vitro activity against MDR isolates of S. maltophilia. 
Chung et al. (8) reported that tigecycline and 
levofloxacin have shown good in vitro activity against 
clinical isolates of S.maltophilia. Other variable 
findings regarding colistin activity against S. 
maltophilia isolates were reported (21). This could be 
explained by differences in the susceptibility testing 
methods. 
                                                                                                                                                                                          
Levofloxacin, as one of the new fluoroquinolones, 
was found to be moderately effective against S. 
maltophilia, in our study, with 81.25% susceptibility 
ratio. Similar data from worldwide SENTRY studies 
has revealed 83.4% sensitivity ratio of S. maltophilia to 
levofloxacin during the period 2003–2008 (22) which 
was decreased to 77.3% in2011 (23). Lower 
susceptibility rates ranging from 64–69.6% have been 
reported in Canada (20), China (24,25), and Korea (8). 
However, it exhibited better potency against S. 
maltophilia than ceftazidime or ticarcillin-clavulanate 
in our study, which comes consistent with Chang et 
al. (3) who reported the same finding. 
Trimethoprim/sulfamethoxazole has been considered 
as the mainstay of therapy against S.maltophilia 
infections. This is primarily based on in vitro 
susceptibility data rather than clinical studies. 
However, increasing resistance to 
trimethoprim/sulfamethoxazole has been reported by 
several studies and has been mostly related to the 
horizontal spread of mobile genetic elements carrying 
resistance genes (16). 
                                                                                                                                                                                                              
In our study, 37.5% of S. maltophilia isolates showed 
SXT resistance. This comes much higher than a 
previous Egyptian study done in Mansoura city, 
which revealed SXT-resistance only in 4.55% of their 
isolates (26). This also comes in contrast to Chung et 
al. (8) who stated that resistance rates vary 
geographically but are generally lesst han 10%. This 
difference could be attributed to increased usage of 
SXT in our local setting. However, high and various 
rates of resistance to SXT have been reported in 
patients with cancer, cystic fibrosis and in several 
countries, including Taiwan, Japan, Korea, Thailand, 
Spain, Mexico, Saudi Arabia, Turkey, and Canada
(16–78.8%) (3). The sul genes and integron 1 were 
tested in all the 32 S. maltophilia isolates, in our study. 
All of the 12 SXT-resistant isolates harbored sul1 gene. 
One isolate among them was additionally positive for 
sul2 gene. All of the 12SXT-resistant isolates had 
positive results for integron 1 as well. On the other 
hand, sul3 gene has not been detected in any of our 
isolates.            
                                                                                                                             
Several investigators have reported that sul1 genes 
associated with class 1 integrons are the major 
mechanism of SXT resistance in S. maltophilia. In a 
survey of 55 S. maltophilia isolates (30 sensitive and 25 
resistant) by PCR, Toleman et al. (27) found that 17 of 
25 resistant isolates possessed the sul1 gene and class 
1 integron. Similarly Chang et al. (28) reported that 26 
out of 100 (26%) S. maltophilia isolates were resistant 
to SXT, with 81% sul1-positive andc arrying class 1 
integron. Liaw et al. (29) reported an increased class 1 
integron presence in S. maltophilia isolates (15 out of 
17, 88%), with 73% (n=11) carrying the sul1 gene. 
Song et al. (30) reported that none of the isolates 
without sul1 had a class 1 integron. These data along 
with our data underline the high prevalence of class 1 
integron in SXT-resistant clinical isolates of S. 
maltophilia. Only 2 of the 20 SXT-susceptible isolates 
were found to yield positive PCR results for sul gene, 
one of them had integron 1. This is in line with other 
researchers who reported the presence of sul genes in 
SXT susceptible S. maltophilia isolates (30,31). 
However, others reported absence of sul genes in 
SXT-susceptible isolates. (27,32) 
                                                                                                                                                                                              
It is worth mentioning that the co-presence of a class 1 
integron gene cassette and the sul1 gene in S. 
maltophilia can further lead to the development of 
multi-drug resistance and may act as a potential 
source for the dissemination of resistance. This indeed 
confirms the importance of strict application of 
infection control measures in order to decrease the 
incidence of infections caused by this serious world 
wide intrinsically drug-resistant pathogen. 
 
Conclusion                                                                                  
In conclusion, this study highlighted the widespread 
of co-trimoxazole resistance among S. maltophilia 
isolated from Zagazig University Hospitals, which 
was much associated with sul1 gene and class 1 
integorn. This necessitates continuous surveillance of 
antimicrobial drug resistance and careful 
epidemiological monitoring of co-trimoxazole 
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resistance, which has the potential to spread by means of mobile genetic elements. 
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